Sign In
Buy TAK
$17.09
-0.160 (-0.93%)
At Close: Jul 31, 2026
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Applicatio
What's Going On With Takeda Stock On Friday?
11:21am, Friday, 22'nd Aug 2025
On Friday, Takeda Pharmaceutical Co Ltd's TAK stock wobbled after touching as low as $14.53 during the premarket session, before bouncing back to about $15.47 at last check Friday.
Japan's Takeda weighs India for global trials to speed up drug launches
01:51am, Thursday, 21'st Aug 2025
Japanese drugmaker Takeda Pharmaceutical is exploring the option of conducting global clinical trials in India to accelerate the launch of its innovative drugs in the world's most populous nation, its
Cosmo and Takeda Renew Strategic Manufacturing Agreement for Global Supply of Oral Treatment for Ulcerative Colitis
01:18am, Friday, 08'th Aug 2025
Dublin, Ireland--(Newsfile Corp. - August 8, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN), a global leader in AI-driven healthcare and specialty pharmaceuticals, today announced the renewal of its m
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
08:31am, Friday, 01'st Aug 2025
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo
President Trump demands drugmakers slash prices within 60 days
06:54am, Friday, 01'st Aug 2025
CNBC's Joe Kernen reports on the latest news.
Takeda Pharmaceutical Company Limited (TAK) Q1 FY2025 Earnings Call Transcript
11:50am, Wednesday, 30'th Jul 2025
Takeda Pharmaceutical Company Limited (NYSE:TAK ) Q1 FY2025 Earnings Call July 30, 2025 6:00 AM ET Company Participants Furuta - Corporate Participant O'Reilly - Corporate Participant Plump - Corporat
Takeda Announces First-Quarter FY2025 Results With Significant Late-Stage Pipeline Progression
02:41am, Wednesday, 30'th Jul 2025
OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the first quarter of fiscal year 2025 (three months ended June 30, 2025), with generic erosion of VYVAN
Takeda Receives FDA 510(k) Clearance for HyHubTM and HyHubTM Duo Devices to Simplify HYQVIA® Administration
08:00am, Monday, 21'st Jul 2025
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for HyHubTM and HyHubTM Duo,
Takeda: Positioned To Tackle Future Clinical Demand In A Highly Regulated Sector
11:32am, Thursday, 17'th Jul 2025
In my followup on Takeda Pharmaceutical Co (TAK), I am reaffirming my buy rating from March. Clinical demand in multiple areas, along with an active drug pipeline, could keep driving the top-line desp
Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (TAK-861) in Narcolepsy Type 1
03:00am, Monday, 14'th Jul 2025
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that all primary and secondary endpoints were met in two Phase 3 randomized, double-blind, placebo-controll
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved GAMMAGARD LIQUID ERC [immune globulin infusio
ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today?
09:56am, Wednesday, 25'th Jun 2025
ADMA's surging Asceniv demand and bold revenue forecasts set it apart in the competitive plasma therapies space.
Takeda Announces New Assignments of Directors
03:07am, Wednesday, 25'th Jun 2025
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) has announced new assignments of directors, determined at the Board of Directors meeting, following the 149th Annual Meet
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) approved ADCETRIS® (brentuximab vedotin) in combination with etoposide,
